

\$ % ^ Other;HighlightOn=\*\*;HighlightOff=\*\*;  
Trying 81800...Open

**PLEASE ENTER HOST PORT ID:**

## INVALID PORT POOL ID ENTERED

**PLEASE REENTER**

LOGIND:d18

**PASSWORD:**

TERMINAL (ENTER 1, 2, 3, 4, OR ?):3

FILE 'USPAT' ENTERED AT 09:15:48 ON 23 SEP 1997

\* \* \* \* \*  
\* WELCOME TO THE \*  
\* U. S. PATENT TEXT FILE \*  
\* \* \* \* \*

=> s leptin  
L1 3 LEPTIN

=> d 1-3

1. 5,395,929, Mar. 7, 1995, Isolated nucleic acid encoding the alpha subunit of the human leukocyte adhesion receptor; Angel A. Corbi, et al., 536/23.5; 435/320.1; 530/399; 536/23.51 :IMAGE AVAILABLE:

2. 5,320,942, Jun. 14, 1994, Method of diagnosing the presence of abnormal epithelial tissue using monoclonal antibodies to the A.sub.6 B.sub.4 cell surface protein; Vito Quaranta, et al., 435/7.23; 530/388.2, 388.8, 388.85 :IMAGE AVAILABLE:

3. 4,220,789, Sep. 2, 1980, Phosphoric esters derived from 1,2,4-triazole having an insecticidal, nematocidal and acaricidal action, and their preparation; Franco Gozzo, et al., 548/263.2, 118, 263.4, 263.6, 264.6 :IMAGE AVAILABLE:

=> s ob or obesity  
3756 OB  
1954 OBESITY  
L2 5639 OB OR OBESITY

=> s gene(3a)therap?  
14045 GENE  
72658 THERAP?  
L3 805 GENE(3A)THERAP?

=> s l2 and l3  
L4 15 L2 AND L3

=> d 1-15

1. 5,661,126, Aug. 26, 1997, Use of mullerian inhibiting substance for treating certain tumors and for modulating class I major histocompatibility antigen expression; Patricia K. Donahoe, et al., 514/12; 435/68.1, 69.1; 530/413 :IMAGE AVAILABLE:

2. 5,658,955, Aug. 19, 1997, Combined use of dopamine and serotonin agonists in the treatment of immune disorders; Pietr Hitzig, 514/654, 885 :IMAGE AVAILABLE:

3. 5,658,568, Aug. 19, 1997, Cytotoxic drug therapy; Kenneth Dawson Bagshawe, 424/134.1, 94.1, 136.1, 155.1, 183.1, 809; 436/819; 514/2; 530/350, 387.3, 387.7, 389.7, 391.7 :IMAGE AVAILABLE:

4. 5,652,224, Jul. 29, 1997, Methods and compositions for \*\*gene\*\* \*\*therapy\*\* for the treatment of defects in lipoprotein metabolism; James M. Wilson, et al., 514/44; 424/93.21; 435/172.3, 320.1, 325, 354, 366, 369, 370 :IMAGE AVAILABLE:

5. 5,650,501, Jul. 22, 1997, Serine/threonine kinase and nucleic acids

encoding same; James W. Dennis, et al., 536/23.2; 435/69.1, 194, 320.1, 325, 348, 352, 358, 365, 367, 419; 530/324, 350; 536/24.1, 24.31 :IMAGE AVAILABLE:

6. 5,646,040, Jul. 8, 1997, Mammalian tub gene; Patrick W. Kleyn, et al., 435/325, 320.1, 348, 357, 358, 364, 365, 369, 419; 536/23.5, 24.3, 24.31 :IMAGE AVAILABLE:

7. 5,614,187, Mar. 25, 1997, Specific tolerance in transplantation; David H. Sachs, 424/93.21, 93.3, 577; 435/172.3; 536/23.1, 23.5 :IMAGE AVAILABLE:

8. 5,599,560, Feb. 4, 1997, Method of treating depression using neurotrophins; Judith Siuciak, 424/570; 514/2, 12; 530/399 :IMAGE AVAILABLE:

9. 5,597,899, Jan. 28, 1997, Tumor necrosis factor muteins; David Banner, et al., 530/351; 435/69.1, 69.5; 530/402 :IMAGE AVAILABLE:

10. 5,597,709, Jan. 28, 1997, Human growth hormone splice variants hGHV-2(88) and hGHV-3(53); Craig A. Rosen, et al., 435/69.4, 69.1, 252.3, 320.1; 536/23.1, 23.51 :IMAGE AVAILABLE:

11. 5,593,837, Jan. 14, 1997, Clinical disorders associated with carboxypeptidase E mutation; J urgen K. Naggert, et al., 435/6; 424/94.63; 435/212; 436/63, 811 :IMAGE AVAILABLE:

12. 5,591,625, Jan. 7, 1997, Transduced mesenchymal stem cells; Stanton L. Gerson, et al., 435/366; 424/93.21, 93.7; 435/172.3, 320.1; 935/62, 70, 71 :IMAGE AVAILABLE:

13. 5,569,604, Oct. 29, 1996, Calcitonin/calcitonin gene related peptide enhancer element and associated DNA binding proteins; Andrew F. Russo, et al., 435/353, 252.3, 320.1; 536/24.1, 24.31 :IMAGE AVAILABLE:

14. 5,550,021, Aug. 27, 1996, Allelic diagnosis of susceptibility to compulsive disorder; Kenneth Blum, et al., 435/6, 91.1, 91.2, 810; 536/23.1, 23.5, 24.31, 24.33; 935/76, 77, 78 :IMAGE AVAILABLE:

15. 5,500,343, Mar. 19, 1996, Allelic association of the human dopamine(D2) receptor gene in compulsive disorders; Kenneth Blum, et al., 435/6, 91.1, 91.2, 810; 536/23.1, 23.5, 24.33; 935/31, 78 :IMAGE AVAILABLE:

= > d 4 ab

US PAT NO: 5,652,224 :IMAGE AVAILABLE: L4: 4 of 15

**ABSTRACT:**

The invention provides a recombinant viral vector comprising the DNA of, or corresponding to, at least a portion of the genome of an adenovirus, which portion is capable of infecting a hepatic cell; and a human VLDL receptor gene operatively linked to regulatory sequences directing its expression. The vector is capable of expressing the normal VLDL receptor gene product in hepatic cells in vivo or in vitro. This viral vector is useful in the treatment of metabolic disorders caused by the accumulation of LDL in plasma, such as familial hypercholesterolemia or familial combined hyperlipidemia.

= > d his

L1        3 S LEPTIN  
L2        5639 S OB OR OBESITY  
L3        805 S GENE(3A)THERAP?  
L4        15 S L2 AND L3

=> logoff y  
U.S. Patent & Trademark Office LOGOFF AT 09:18:20 ON 23 SEP 1997